Adding Ipilimumab to Nivolumab No Better in Pretreated Squamous NSCLC
No difference in overall survival seen with nivolumab plus ipilimumab, nivolumab alone for advanced, chemotherapy-pretreated disease
No Benefit Seen From Adjuvant Celecoxib in ERBB2-Negative Breast Cancer
Disease-free survival did not improve with two years of celecoxib versus placebo in ERBB2-negative breast cancer
Outpatient Antibiotic Prescribing Down in VA System
Annual percent decrease for all outpatient antibiotic use averaged 3.9 percent; largest decrease seen in ciprofloxacin use at 12.6 percent
Neutralizing Monoclonal Antibody Combo Treats Mild, Moderate COVID-19
For those at high risk, COVID-19-related hospitalization or death from any cause reduced with bamlanivimab/etesevimab versus placebo
Physician’s Briefing Weekly Coronavirus Roundup
FDA to Prioritize Full Approval for Pfizer COVID-19 Vaccine
Full approval could help boost vaccination efforts in the United States
$345 Million Settlement Proposed in EpiPen Lawsuits
Pfizer spokesperson denied any wrongdoing and said settlement was sought to avoid 'the distraction of continued litigation'
Canada May Open Borders to Fully Vaccinated Americans by Mid-August
However, mask mandate returns to Los Angeles as COVID-19 cases rise
CDC Advisers to Discuss Third COVID-19 Vaccine Dose for Immunocompromised
Booster shots have become a hot topic since Pfizer-BioNTech said last week it would seek EUA for a third shot of its two-dose vaccine
U.S. Surgeon General Issues Call to Counter ‘Urgent Threat’ of Vaccine Misinformation
Warning comes as the pace of COVID-19 vaccinations has slowed throughout the United States
